

## ***Request under Freedom of Information Act 2000***

Thank you for your request for information which we received on 12 October 2018.

I am pleased to confirm the following.

- 1) Does your Trust have a policy on the use of unlicensed medicines? Please Answer Yes or No. If yes, please provide a copy of the policy.**

Yes, please find attached.

- 2) Does your Trust have a policy or protocol on obtaining informed consent from patients when an unlicensed medicine is used? Please answer Yes or No. If yes, please provide copies of all relevant documentation including copies of template informed consent materials used to consent patients where an unlicensed medicine is to be administered.**

Yes

See link above for relevant policy

- 3) Please state which Board level job role(s) is (are) responsible for patient safety and consenting.**

Director of Patient Care / Chief Nurse  
Medical Director

- 4) Does your Trust have, or intend to introduce, a policy that makes compounded bevacizumab routinely available to treat wet age-related macular degeneration? If yes please supply a copy of your policy.**

No

- 5) Does your Trust currently have a wholly NHS owned pharmacy with an aseptic unit for compounding/aliquotting medicines? Please answer Yes or NO. If yes, is this NHS pharmacy the same legal entity as that of your hospital Trust?**

No

- 6) Does your Trust currently host on its premises a privately owned pharmacy with an aseptic unit for compounding/aliquotting medicines? Please answer Yes or NO. If yes, please provide details of the third party provider of your pharmacy services.**

No

7) **Over the past two years has your Trust, on more than one occasion, used compounded Avastin (bevacizumab) for ophthalmic use? Please answer Yes or No.**

Yes

**If you answered yes to Q5 or Q6:**

8) **Is the pharmacy referred to above in Q5 or Q 6 currently providing, or potentially able to provide, compounded Avastin (bevacizumab) for ophthalmic use? Please answer Yes or No**

N/A

9) **Does the pharmacy referred to above in Q5 or Q6 currently hold an MHRA license for the manufacture of specials? Please answer Yes or No**

N/A

**If you answered yes to Q5 or Q6 but no to Q9:**

10) **When was the pharmacy referred to above in answer to Q5 or Q6 last inspected by the CQC?**

N/A

**If you answered no to questions Q5 or Q6 above, but yes to question Q7:**

11) **Please provide information regarding from whom your Trust has or obtained/purchased compounded Avastin (bevacizumab). If you cannot provide the name of any commercial supplier, please provide as much information as possible.**

ITH Pharma

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom Of Information Co-ordinator

For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the  
'Re-use of Public Sector Information Regulations' and best practice.